Table 3.
Characteristics of Relapsed Patients
| Patient | Age at dx (years) | Gender | Tumor Location | hCGβ (IU/L) in Serum/CSF at Diagnosis | CT Response* | Relapse Location | Time to Relapse From Start of RT (months) | Dose of WVI (Gy) | Evaluability |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 20.21 | Male | Brain Ventricle | 1/3 | CCR | Spine | 9.98 | 18 | Evaluable |
| 2 | 9.86 | Female | Suprasellar | 3/2 | CCR | Primary site | 24.92 | 24 | Not evaluable No tumor markers after completion of CT |
| 3 | 10.92 | Female | Pineal Gland | 2/medically contraindicated | PR | Positive CSF | 1.98 | 24 | Evaluable |
| 4 | 7.52 | Female | Suprasellar | 27/26.8 | CCR | Left parietal | 11.40 | 18 |
Not evaluable
No tumor markers after completion of CT |
| 5 | 17.00 | Male | Bifocal | 2.4/1 | CR | Spine | 9.71 | 18 | Evaluable |
| 6 | 9.61 | Male | Pineal Gland | 2/6.3 | CCR | Right parietal | 4.89 | 18 | Evaluable |
| 7 | 13.82 | Male | Bifocal | 6.3/6.8 | CCR | Right frontal | 21.32 | 18 | Evaluable |
| 8 | 17.48 | Male | Pineal Gland | 46/80 | CCR | Right frontal, pineal, spinal | 23.40 | 24 | Evaluable |
Bifocal, pineal and suprasellar location; CCR, continued complete response; CR, complete response; PR, partial response; CT, chemotherapy; RT, radiation therapy.